Equity Overview
Price & Market Data
Price: $2.65
Daily Change: +$0.09 / 3.40%
Daily Range: $2.51 - $2.65
Market Cap: $386,634,144
Daily Volume: 5,240
Performance Metrics
1 Week: 21.33%
1 Month: 34.03%
3 Months: 54.22%
6 Months: 39.13%
1 Year: 789.2%
YTD: 57.06%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.